Humacyte Announces Three Presentations At American Heart Association Scientific Sessions, November 6–9; Two Additional Presentations To Cover First-In-Human Phase 2a Study Design And Preclinical Results For Its Investigational Coronary Tissue Engineered Vessel

AHA Scientific Sessions is one of the world’s largest gatherings of cardiovascular clinicians and scientists. Humacyte’s presentations include an invited talk by the company’s Founder, President and Chief Executive Officer, Laura Niklason, M.D., Ph.D., and two presentations highlighting Humacyte’s investigational coronary tissue engineered vessel (CTEV), a small-diameter bioengineered vessel for coronary artery bypass grafting (CABG).

"AHA brings together the cardiac surgeons and cardiologists who will ultimately decide whether an off-the-shelf conduit belongs in bypass surgery, and we are excited for them to see our preclinical data and our study design firsthand," said Dr. Niklason. "Our approach is built on the idea that the body can repopulate an engineered vessel with a patient’s own cells. With the CTEV, we are taking the next step toward bringing bioengineered vascular technology to coronary bypass surgery through the first U.S. clinical trial of a bioengineered CABG conduit."

Presentation details:

Invited Talk

Title: Engineering the Microenvironment to Accelerate Vascular Regeneration
Presenter: Laura E. Niklason, M.D., Ph.D., Founder and CEO, Humacyte, Inc.
Date and time: Saturday, November 7, 2026, 10:15 AM CT
Location: North Hall, Level 3, McCormick Place, Chicago
Clinical Study Design

Title: First-in-Human Phase 2a Study Design of a Bioengineered Human Coronary Artery for Coronary Artery Bypass Grafting
Presenters: John Alexander, M.D., M.H.S., Professor of Medicine/Cardiology, Duke Clinical Research Institute at Duke University and Alan Kypson, M.D., Cardiothoracic Surgeon, UNC Rex Hospital
Date and time: Saturday, November 7, 2026, 3:57 PM CT
Session/Location: Science and Technology Hall, Level 3, Clinical Science Zone 1, McCormick Place, Chicago
Preclinical CABG Results

Title: Evaluation of Tissue Engineered Human Vessels in Porcine and Ovine Models of Coronary Artery Bypass Grafting
Presenter: Robert Kirkton, Ph.D., Executive Director of New Product and Process Development, Humacyte, Inc.
Date and time: Sunday, November 8, 2026, 9:15 AM CT
Session/Location: Science and Technology Hall, Level 3, Clinical Science Zone 2, McCormick Place, Chicago
The CTEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.